Eli Lilly is taking six companies to court to stamp out a booming “black market” for retatrutide — a powerful weight-loss drug that isn’t approved anywhere in the world.
Retatrutide is Lilly’s experimental “triple-G” obesity medicine, which hits three hormone receptors at once and, in trials, has produced weight loss in some cases rivaling bariatric surgery. But it is still investigational; Lilly plans to file for FDA approval in 2027. Despite that, sellers are already marketing unapproved versions online as a weight-loss “hack.”
Who’s being sued
On August 12, 2026, Lilly filed six lawsuits against entities including Aesthetic Envy, Astra Peptides, Legendary Peptides, Texas Peptides, Lone Star Peptide and Striker Pharmacy — a mix of compounding pharmacies, med spas, wellness clinics and online “peptide” sellers, some posing as legitimate medical providers.
The safety stakes
Because no regulator has vetted these products, Lilly warns the copies “could be fake, impure or mis-dosed,” posing serious health risks. The company says it has already referred more than 200 people and entities to regulators and law enforcement and flagged over 14,000 websites, ads and posts across 100-plus countries. The gray market surged after GLP-1 shortages; even with those shortages declared over, compounders keep capturing demand — and, with an unapproved drug like retatrutide, doing so entirely outside the regulated system.